Lytix Biopharma AS is a private biopharmaceutical company with a range of regional and national Norwegian investors. The company has attracted significant interest from equity financing sources as well as substantial project funding from the Norwegian Research Council. The company will seek to fund further development of its pipeline through a combination of own funds, licensing revenues, join ventures and Public-Private collaborations.